Cargando…

Establishment and Characterization of a Novel Dedifferentiated Chondrosarcoma Cell Line DDCS2

BACKGROUND: The dedifferentiated variant of chondrosarcoma is highly aggressive and carries an especially grim prognosis. While chemotherapeutics has failed to benefit patients with dedifferentiated chondrosarcoma significantly, preclinical chemosensitivity studies have been limited by a scarcity of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaoyang, Dean, Dylan C., Ferreira, Al, Nelson, Scott D., Hornicek, Francis J., Yu, Shengji, Duan, Zhenfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645311/ https://www.ncbi.nlm.nih.gov/pubmed/34767468 http://dx.doi.org/10.1177/10732748211045274

Ejemplares similares

Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma
por: Li, Xiaoyang, et al.
Publicado: (2020)

The molecular pathogenesis of dedifferentiated chondrosarcoma
por: Sakamoto, Akio
Publicado: (2014)

T‐LAK cell‐originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma
por: Thanindratarn, Pichaya, et al.
Publicado: (2020)

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
por: van Oosterwijk, Jolieke G, et al.
Publicado: (2012)

Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma
por: Liu, Pei, et al.
Publicado: (2017)

Advances in immune checkpoint inhibitors for bone sarcoma therapy
por: Thanindratarn, Pichaya, et al.
Publicado: (2019)

Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment
por: Lex, Johnathan R., et al.
Publicado: (2018)

TCF-1 participates in the occurrence of dedifferentiated chondrosarcoma
por: Xu, Xiaolong, et al.
Publicado: (2016)

Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution
por: Miao, Ruoyu, et al.
Publicado: (2019)

SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
por: Guo, Tao, et al.
Publicado: (2022)

Putative Multifunctional Signature of Lung Metastases in Dedifferentiated Chondrosarcoma
por: Malchenko, Sergey, et al.
Publicado: (2012)

Dedifferentiated chondrosarcoma of the cervical spine: a case report
por: Matsumoto, Yoshihiro, et al.
Publicado: (2013)

Dedifferentiated Peripheral Chondrosarcoma: A Review of Radiologic Characteristics
por: Henderson, Eric R., et al.
Publicado: (2013)

C‐reactive protein: An independent predictor for dedifferentiated chondrosarcoma
por: Nemecek, Elena, et al.
Publicado: (2018)

Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation
por: Wang, Kun, et al.
Publicado: (2021)

The role of extracelluar matrix in osteosarcoma progression and metastasis
por: Cui, Juncheng, et al.
Publicado: (2020)

Expression and Clinical Significance of High‐Mobility Group AT‐hook 2 (HMGA2) in Osteosarcoma
por: Cui, Juncheng, et al.
Publicado: (2022)

Metastatic Dedifferentiated Chondrosarcoma to Thyroid Gland: A Case Report
por: Aladily, Tariq N., et al.
Publicado: (2021)

Exosomes promote pre-metastatic niche formation in ovarian cancer
por: Feng, Wenlong, et al.
Publicado: (2019)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Thanindratarn, Pichaya, et al.
Publicado: (2021)

Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067
por: Shen, Shen, et al.
Publicado: (2020)

Massive dedifferentiated chondrosarcoma affecting whole mandible with high recurrence potential
por: Mishra, Niranjan, et al.
Publicado: (2015)

Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials
por: Zając, Weronika, et al.
Publicado: (2023)

Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study
por: Wei, Ran, et al.
Publicado: (2020)

Dedifferentiated chondrosarcoma with leukocytosis and elevation of serum G-CSF. A case report
por: Sakamoto, Akio, et al.
Publicado: (2006)

Dedifferentiated Chondrosarcoma of Proximal Tibia and Fibula with an Infected Ulcer: A Case Report
por: Pattanashetty, O.B., et al.
Publicado: (2016)

Dedifferentiated chondrosarcoma: Radiological features, prognostic factors and survival statistics in 23 patients
por: Liu, Chenglei, et al.
Publicado: (2017)

Association of Preoperative Neutrophil/Lymphocyte Ratio with Clinical Outcomes in Dedifferentiated Chondrosarcoma Patients
por: Liu, Chenglei, et al.
Publicado: (2020)

Dedifferentiated Central Chondrosarcoma: A Clinical, Histopathological, and Immunohistochemical Analysis of 57 Cases
por: Gong, Li-Hua, et al.
Publicado: (2021)

Appendicular dedifferentiated chondrosarcoma: A management and survival study from the SEER database
por: Gonzalez, Marcos R., et al.
Publicado: (2022)

Noncoding RNA in drug resistant sarcoma
por: Li, Xiaoyang, et al.
Publicado: (2017)

Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma
por: Tsuchiya, Ryuto, et al.
Publicado: (2021)

ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer
por: Feng, Wenlong, et al.
Publicado: (2020)

Proximal epithelioid sarcomatous dedifferentiation in secondary chondrosarcoma in a known case of multiple osteochondromatosis
por: Dey, Biswajit, et al.
Publicado: (2017)

Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
por: Singh, Amisha, et al.
Publicado: (2022)

A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma
por: Bui, Nam, et al.
Publicado: (2023)

Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma
por: Dermawan, Josephine Kam Tai, et al.
Publicado: (2023)

Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma
por: Feng, Wenlong, et al.
Publicado: (2020)

Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute
por: Yokota, Kazuya, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_iqvcdemt4ks43h1g6fadplrgcu